Answers are grounded in this paper and cite their sources.
Evaluates efficacy and safety of lenadogene nolparvovec gene therapy in Leber hereditary optic neuropathy, indicating its potential benefits.
To provide efficacy and safety data on the use of lenadogene nolparvovec gene therapy (LNGT) in real-life conditions in patients with Leber hereditary optic neuropathy (LHON) caused by the m.11778G>A ND4 variant.
No takes yet. Share an insight, caveat, or question.
Newman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: